SU1053750A3 - Способ получени производных изоксазола - Google Patents
Способ получени производных изоксазола Download PDFInfo
- Publication number
- SU1053750A3 SU1053750A3 SU813261940A SU3261940A SU1053750A3 SU 1053750 A3 SU1053750 A3 SU 1053750A3 SU 813261940 A SU813261940 A SU 813261940A SU 3261940 A SU3261940 A SU 3261940A SU 1053750 A3 SU1053750 A3 SU 1053750A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- group
- alkyl
- oxy
- stands
- amino
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 150000002545 isoxazoles Chemical class 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 1
- -1 carbamoylamino-oxy Chemical group 0.000 abstract description 4
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- OHUCPYWPUWLNQI-UHFFFAOYSA-N 3-(bromomethyl)-1,2-oxazole Chemical compound BrCC=1C=CON=1 OHUCPYWPUWLNQI-UHFFFAOYSA-N 0.000 description 1
- DKBISLDZVNXIFT-UHFFFAOYSA-N 5-(bromomethyl)-1,2-oxazole Chemical compound BrCC1=CC=NO1 DKBISLDZVNXIFT-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229910052811 halogen oxide Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- NOVHEGOWZNFVGT-UHFFFAOYSA-N hydrazine Chemical compound NN.NN NOVHEGOWZNFVGT-UHFFFAOYSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU8080637A HU180567B (en) | 1980-03-19 | 1980-03-19 | Method for producing derivatives of isooxazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1053750A3 true SU1053750A3 (ru) | 1983-11-07 |
Family
ID=10950573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813261940A SU1053750A3 (ru) | 1980-03-19 | 1981-03-19 | Способ получени производных изоксазола |
| SU823414099A SU1152518A3 (ru) | 1980-03-19 | 1982-04-01 | Способ получени производных изоксазола |
| SU823416146A SU1158044A3 (ru) | 1980-03-19 | 1982-04-01 | Способ получени 3-метил-4-хлор-5-бромэтиламинометилизоксазола или его гидрохлорида |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823414099A SU1152518A3 (ru) | 1980-03-19 | 1982-04-01 | Способ получени производных изоксазола |
| SU823416146A SU1158044A3 (ru) | 1980-03-19 | 1982-04-01 | Способ получени 3-метил-4-хлор-5-бромэтиламинометилизоксазола или его гидрохлорида |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS56158774A (enExample) |
| BE (1) | BE887954A (enExample) |
| CA (1) | CA1163631A (enExample) |
| CH (1) | CH646157A5 (enExample) |
| DE (1) | DE3110817A1 (enExample) |
| DK (3) | DK151012C (enExample) |
| ES (3) | ES8302674A1 (enExample) |
| FI (1) | FI70011C (enExample) |
| FR (1) | FR2478634A1 (enExample) |
| GB (1) | GB2075009B (enExample) |
| HU (1) | HU180567B (enExample) |
| IT (1) | IT1211010B (enExample) |
| SE (1) | SE454695B (enExample) |
| SU (3) | SU1053750A3 (enExample) |
| YU (1) | YU42560B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100260A (en) * | 1997-04-21 | 2000-08-08 | Sumitomo Pharmaceutical Company, Limited | Isoxazole derivatives |
| ID22897A (id) * | 1997-04-21 | 1999-12-16 | Sumitomo Pharmaceutical Compan | Turunan isoksazol |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL302496A (enExample) * | 1962-12-22 | |||
| US3808221A (en) * | 1971-04-14 | 1974-04-30 | Hoffmann La Roche | Antiandrogenic n-(3,5-dilower alkyl-4-heterocyclic)methyl)phthalimides |
-
1980
- 1980-03-19 HU HU8080637A patent/HU180567B/hu not_active IP Right Cessation
-
1981
- 1981-03-16 BE BE1/10179A patent/BE887954A/fr not_active IP Right Cessation
- 1981-03-17 YU YU689/81A patent/YU42560B/xx unknown
- 1981-03-17 SE SE8101703A patent/SE454695B/sv not_active IP Right Cessation
- 1981-03-18 FR FR8105378A patent/FR2478634A1/fr active Granted
- 1981-03-18 CH CH182981A patent/CH646157A5/de not_active IP Right Cessation
- 1981-03-18 IT IT8120395A patent/IT1211010B/it active
- 1981-03-18 FI FI810838A patent/FI70011C/fi not_active IP Right Cessation
- 1981-03-18 DK DK122581A patent/DK151012C/da not_active IP Right Cessation
- 1981-03-18 GB GB8108545A patent/GB2075009B/en not_active Expired
- 1981-03-18 ES ES501095A patent/ES8302674A1/es not_active Expired
- 1981-03-19 JP JP4023281A patent/JPS56158774A/ja active Pending
- 1981-03-19 CA CA000373380A patent/CA1163631A/en not_active Expired
- 1981-03-19 SU SU813261940A patent/SU1053750A3/ru active
- 1981-03-19 DE DE19813110817 patent/DE3110817A1/de not_active Withdrawn
-
1982
- 1982-04-01 SU SU823414099A patent/SU1152518A3/ru active
- 1982-04-01 SU SU823416146A patent/SU1158044A3/ru active
- 1982-04-16 ES ES511895A patent/ES8305340A1/es not_active Expired
- 1982-04-16 ES ES511894A patent/ES8401758A1/es not_active Expired
-
1987
- 1987-01-16 DK DK023087A patent/DK151959C/da not_active IP Right Cessation
- 1987-01-16 DK DK023187A patent/DK153549C/da not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| 1. За вка FR № 2419289, кп. С O7l.261/O8, опубл. 1979. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU820659A3 (ru) | Способ получени производных 4-амино- 5-АлКилСульфОНилОАНизАМидОВ, иХ СОлЕй,ОКиСЕй, лЕВО- и пРАВОВРАщАющиХизОМЕРОВ /иХ ВАРиАНТы/ | |
| KR100371297B1 (ko) | 치환된티아졸리딘디온유도체 | |
| SU1436872A3 (ru) | Способ получени производных пиримидина | |
| JPH01246265A (ja) | ４‐ピリドン‐３‐カルボン酸誘導体 | |
| US4067982A (en) | Aryl-substituted piperazinyl-alkylamino-uracils, -uracil ethers and -uracil thioethers as therapeutics | |
| DK162638B (da) | Analogifremgangsmaade til fremstilling af 6-fluor-1,4-dihydro-4-oxo-3-quinolincarboxylsyrederivater og udgangsmateriale til brug ved fremgangsmaaden | |
| AU574129B2 (en) | Arylacetic acid derivatives | |
| US5258397A (en) | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions | |
| IL23338A (en) | N-phenylpiperazine compounds | |
| IE49541B1 (en) | 4,5-dihydro-1-(3-mercapto-1-oxopropyl)-3-phenyl-1h-pyrazole-5-carboxylic acid and derivatives thereof | |
| SU1053750A3 (ru) | Способ получени производных изоксазола | |
| ES2519441T3 (es) | Compuestos para tratar la impotencia | |
| JPH033669B2 (enExample) | ||
| JPH0699307B2 (ja) | 抗痴呆剤 | |
| KR920005827B1 (ko) | 벤조티아디아제핀 유도체 | |
| SU784763A3 (ru) | Способ получени производных 6- метокси-2-ацетилнафтилоксима или их хлоргидратов | |
| US3833594A (en) | Amino derivatives of pyrazolopyridine carboxylic acids and esters | |
| US4421754A (en) | Syndonimine derivatives, process for production thereof, and use thereof | |
| US3862947A (en) | Intermediate for production of alkoxy derivatives of pyrazolopyridine carboxylic acids and esters | |
| FR2465733A1 (fr) | Nouveaux derives imidazolylethoxymethyliques de 1,3-dioxoloquinoleines utiles notamment comme medicaments antibacteriens et antifongiques, leur procede de preparation et compositions therapeutiques et formes pharmaceutiques les contenant | |
| US3133933A (en) | Certain | |
| US4269848A (en) | 5-Substituted indan-2-carboxylic acid and functional derivatives | |
| JP3553158B2 (ja) | ピリダジノインドール誘導体 | |
| US3697527A (en) | Doethyl phenyl sulfonylureas | |
| JP3059572B2 (ja) | ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体及びこれを有効成分とする高血圧治療剤 |